ALPHA-BLUE-OCEAN
Environmental Performance Financing (EPF), a subsidiary of the Alpha Blue Ocean group, is proud to announce its collaboration with Europlasma (ALEUP:FP), a leader in depollution, material recovery, and decarbonation solutions, for the establishment of a bond financing arrangement.
This financing aims to support the Group's growth and development, particularly in key initiatives such as:
- The acquisition of MG-Valdunes: Europlasma has obtained the green light for the acquisition of MG-Valdunes' business assets, a crucial step towards strengthening industrial sovereignty and relaunching Valdunes' historic activities.
- The development of the Forges de Tarbes: Funds will also be allocated to increasing the production capacities of the Forges de Tarbes, which are facing growing demand, particularly in the defense sector.
- The continued development of historical activities: A significant portion of the funds will be dedicated to the ongoing development of depollution, decarbonation, and hazardous waste recovery activities, a domain in which Europlasma has excelled for years.
This partnership will strengthen Europlasma's market position while contributing to the achievement of essential environmental objectives.
This collaboration illustrates ABO Group's commitment to financing innovative and sustainable environmental projects.
Pierre Vannineuse, CIO and Founder of Alpha Blue Ocean: "We are delighted to announce the renewal of our partnership with Europlasma for a 7th significant financing contract. This long-standing collaboration represents our commitment to supporting innovative and sustainable environmental projects over the long term. After seven years of fruitful collaboration with Europlasma, this new contract once again illustrates the success of our joint efforts. Europlasma embodies a French industrial flagship and an unparalleled global reference in its sector. We are all fully committed to establishing this collaboration on a lasting basis and to maintain the positive momentum that has been built in recent years.”
Jérôme Garnache-Creuillot, CEO Europlasma :
"I would like to thank the ABO team who continues to financially support the significant growth of the Europlasma Group. Without this support, the rescue of Forges de Tarbes in 2021 would have been impossible. Today, their expertise is preserved, and they contribute more each day to the production of large caliber shells. ABO’s loyal support, as well as that of the Economic and Social Development Fund and local authorities, enables Europlasma to save Valdunes, the last French manufacturer of train wheels and axles. Thus, thanks to this funding, another French expertise, once again strategic, is preserved."
About Alpha Blue Ocean:
Established in 2017, Alpha Blue Ocean is a pioneering and leading player in alternative finance in Europe and worldwide, particularly in the field of medical innovation. In 5 years, the group founded by Pierre Vannineuse has executed over 2 billion euros in financial commitments, 60% of which are in the Healthcare & Innovation sectors.
About EUROPLASMA:
Europlasma is a French group with an international presence, dedicated to designing and developing expertise for the benefit of humanity and the environment. A specialist in depollution, its innovative solutions are aimed at the treatment and valorization of hazardous waste using its proprietary technology, the plasma torch, as well as applications for industries concerned with reducing their environmental footprint, through the substitution of fossil fuels or recycling in a circular economy logic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425028344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom